for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sangamo Therapeutics Inc

SGMO.OQ

Latest Trade

10.66USD

Change

0.03(+0.28%)

Volume

1,031,834

Today's Range

10.50

 - 

10.97

52 Week Range

6.28

 - 

17.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.63
Open
10.60
Volume
1,031,834
3M AVG Volume
35.94
Today's High
10.97
Today's Low
10.50
52 Week High
17.35
52 Week Low
6.28
Shares Out (MIL)
115.68
Market Cap (MIL)
1,245.82
Forward P/E
-7.81
Dividend (Yield %)
--

Next Event

Sangamo Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Sangamo Therapeutics Q2 Revenue $17.5 Mln Versus $21.4 Mln

Prathyusha Durabaibu Appointed As Principal Accounting Officer For Sangamo Therapeutics

Sangamo Therapeutics Inc Says On May 13, Kathy Y. Yi Notified Co Of Her Intention To Resign As Evp And CFO, Effective June 7 - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Industry

Biotechnology & Drugs

Contact Info

501 Canal Blvd

+1.510.9706000

https://www.sangamo.com/

Executive Leadership

Alexander D. Macrae

President, Chief Executive Officer, Director

Stephane Boissel

Interim Chief Financial Officer

Prathyusha Durabaibu

Principal Accounting Officer

Adrian Woolfson

Executive Vice President of Research and Development

Edward Rebar

Senior Vice President, Chief Technology Officer

Key Stats

2.13 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.020

2017

-0.700

2018

-0.700

2019(E)

-1.362
Price To Earnings (TTM)
--
Price To Sales (TTM)
16.39
Price To Book (MRQ)
2.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
9.33
LT Debt To Equity (MRQ)
9.33
Return on Investment (TTM)
-18.31
Return on Equity (TTM)
-16.08

Latest News

Sangamo Therapeutics shares dive after poor early-stage trial data

Sangamo Therapeutics Inc's shares sank 27 percent on Thursday after its gene-editing drug failed to show promise in an early-stage trial testing it in patients with ultra-rare disorders.

BioMarin sets stage early for hemophilia cure off-Broadway

(This version of the November 21st story has been refiled to show in paragraph 23 that Sangamo Therapeutics has six people in clinical trials)

BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003

* BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE

BRIEF-Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23

* SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Sangamo Therapeutics Prices Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sangamo Therapeutics Proposes Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sangamo Therapeutics Files For Potential Mixed Shelf Offering

* SANGAMO THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2vH7vVF) Further company coverage:

BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior Executive's Company Email Account

* SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE'S COMPANY EMAIL ACCOUNT

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc <GILD.O> will use Sangamo Therapeutics Inc's <SGMO.O> gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion (2.16 billion pounds) to Sangamo, the companies said on Thursday.

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

BRIEF-Sangamo Therapeutics Q4 Loss Per Share $0.15

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Kite And Sangamo Therapeutics Announce Collaboration To Develop Cell Therapies For Treatment Of Cancer

* KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER

BRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice President

* SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF HEATHER D. TURNER AS SENIOR VICE PRESIDENT AND GENERAL COUNSEL Source text for Eikon: Further company coverage:

BRIEF-Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant

* CASE WESTERN RESERVE AND SANGAMO THERAPEUTICS ANNOUNCE $11 MILLION NIH GRANT FOR STUDY OF GENE-EDITED T CELLS FOR VIRAL ERADICATION OF HIV

Sangamo partners with Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.

BRIEF-Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als

* SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS

BRIEF-Sangamo Therapeutics posts Q3 loss per share $0.15

* Sangamo Therapeutics reports third quarter 2017 financial results

BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400

* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia

BRIEF-Sangamo Therapeutics reports Q2 loss per share $0.17

* Sangamo Therapeutics reports second quarter 2017 financial results

BRIEF-Sangamo Therapeutics appoints Roger Jeffs, Joseph Zakrzewski to its board

* Sangamo Therapeutics appoints Roger Jeffs, PH.D. and Joseph S. Zakrzewski to its board of directors

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up